$OCUL Investment Thesis: A Speculative Buy on Ocular Therapeutix’s Disruptive...
Ocular Therapeutix (NASDAQ: OCUL) is a compelling yet high-risk investment centred around AXPAXLI™, a groundbreaking sustained-release treatment for wet age-related macular degeneration. Targeting a multi-billion dollar market, AXPAXLI's extended-release potential...